Meeting
2016 ASCO Annual Meeting
A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.
Authors
Elisabeth De Vries
University Medical Center Groningen, Groningen, Netherlands
Elisabeth De Vries , Clasina Marieke Venema , Andor W. J. M. Glaudemans , Lorraine Fitzpatrick , Dinesh Purandare , Gary Hattersley , Fiona Garner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT02650817
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS627)
DOI
10.1200/JCO.2016.34.15_suppl.TPS627
Abstract #
TPS627
Poster Bd #
108a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
First Author: Erika P. Hamilton
Poster
2020 ASCO Virtual Scientific Program
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Erika Paige Hamilton
Poster
2017 ASCO Annual Meeting
Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer.
First Author: Aditya Bardia
Poster
2022 ASCO Annual Meeting
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
First Author: Komal L. Jhaveri